title: DLI after haploidentical BMT with post-transplant CY.
abstract: Forty-two patients relapsing after an unmanipulated haploidentical BM transplant and post-transplant CY (PT-CY), were given 108 DLI, with median interval from transplant of 266 days (range, 67-1372). DLI were given at escalating doses, expressed as CD3+ cells/kg, without GVHD prophylaxis, and ranged from 1 × 10(3) to 1 × 10(7) cells/kg (median 5 × 10(5) cells/kg). The average number of DLI per patient was 2.6 (range, 1-6). The diagnosis was leukemias (n=32) grafted with a myeloablative regimen and Hodgkin's disease (n=10), grafted with a nonmyeloablative regimen. Leukemic patients with molecular relapse (n=20), received DLI alone (n=17) or in association with azacytidine (n=3); leukemic patients with hematologic relapse (n=12) received chemotherapy followed by DLI (n=11) or DLI alone (n=1); Hodgkin patients received DLI following 1-3 courses of chemotherapy. In these three groups the incidence of acute GVHD II-III was 15%, 17% and 10%; response rate was 45%, 33% and 70%; 2-year actuarial survival was 43%, 19% and 80% respectively. This study confirms that escalating doses of DLI can be given in the haploidentical setting with PT-CY, with a relatively low risk of acute GVHD. Response rates and survival are dependent on the underlying disease.
authors.affiliation: Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Ghiso
authors.affiliation: Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy.
authors.forename: A M
authors.initials: AM
authors.lastname: Raiola
authors.affiliation: Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Gualandi
authors.affiliation: Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Dominietto
authors.affiliation: Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Varaldo
authors.affiliation: Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy.
authors.forename: M T
authors.initials: MT
authors.lastname: Van Lint
authors.affiliation: Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Bregante
authors.affiliation: Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Di Grazia
authors.affiliation: Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy.
authors.forename: T
authors.initials: T
authors.lastname: Lamparelli
authors.affiliation: Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Galaverna
authors.affiliation: Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Stasia
authors.affiliation: Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Luchetti
authors.affiliation: Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Geroldi
authors.affiliation: Clinica Ematologica, IRCSS San Martino, Genova, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Grasso
authors.affiliation: Clinica Ematologica, IRCSS San Martino, Genova, Italy.
authors.forename: N
authors.initials: N
authors.lastname: Colombo
authors.affiliation: Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Bacigalupo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D064591:Allografts; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001374:Azacitidine / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation; D018572:Disease-Free Survival; D006086:Graft vs Host Disease / Q000401:mortality / Q000517:prevention & control*; D006689:Hodgkin Disease / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D007938:Leukemia / Q000401:mortality / Q000517:prevention & control; D019520:Living Donors; D017710:Lymphocyte Transfusion; D008875:Middle Aged; D012008:Recurrence; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine